Anti-aging and repairing mask as well as preparation method and application thereof

Abstract

The invention provides a mask with efficient repairing, anti-inflammatory and moisturizing functions, the mask is prepared by taking polysulfonic acid mucopolysaccharide as a main active component and other natural components as auxiliary materials through scientific proportioning and a liposome wrapping technology, and the problem that the permeability and the stability of the active components are poor when the polysulfonic acid mucopolysaccharide is used for preparing the mask is solved.

Description

Technical Field

[0001] The present invention relates to the technical field of cosmetics, and specifically relates to a facial mask with polysaccharide mucopolysulfate as the core active ingredient and a preparation method thereof, which is applicable to improving local blood circulation of the skin, scar repair, anti-inflammatory, and promoting the improvement of the skin barrier function. Background Art

[0002] With the improvement of people's living standards and the increasing demand for skin care, facial masks, as an efficient skin care product, have received extensive attention. At present, there are various types of facial masks on the market. Most traditional facial masks are based on water, moisturizers, and thickeners, focusing on basic moisturization with a single function, and have limited effects on skin barrier repair, deep moisturization, or inflammation alleviation. Products with comprehensive effects such as improving skin microcirculation, repairing damaged skin, anti-inflammatory and detumescence, and moisturizing still need to be improved.

[0003] Polysaccharide mucopolysulfate (MPS) is a naturally occurring glycosaminoglycan, a mixture of highly sulfated chondroitin sulfate-like polysaccharide molecules with a molecular weight between 5000 - 15000 daltons. The structural formula of polysaccharide mucopolysulfate is as follows:

[0004]

[0005] Polysaccharide mucopolysulfate widely exists in animal tissues, can promote the synthesis of mesenchymal cells and restore the ability of intercellular substances to retain moisture, and has various biological activities such as anti-inflammatory, antioxidant, moisturizing, anti-thrombosis formation, and promoting connective tissue regeneration. Research shows that MPS can promote fibroblast proliferation and collagen synthesis, and inhibit the activity of matrix metalloproteinases, thus playing an anti-aging and scar repair-promoting role. Polysaccharide mucopolysulfate (such as heparin analogs) is mainly applied to phlebitis in the medical field, but its application in cosmetics has not been fully developed, especially the research and potential application in facial masks are relatively few. Therefore, it is of great practical significance to research and develop a facial mask containing polysaccharide mucopolysulfate.

[0006] Although polysaccharide mucopolysulfate has various physiological activities such as promoting blood circulation, stimulating tissue regeneration, and anti-inflammatory, it has unique physical and chemical properties. Its molecular weight is relatively large and its stability is affected under conditions such as high temperature and light. When developing and applying it to facial mask products, there are many challenges in formula design and preparation process, such as the stability of active ingredients (which may be easily degraded and inactivated by other ingredients in the formula), transdermal efficiency (the skin permeability needs to be improved through carrier optimization), and potential difficulties in compatibility with other ingredients (such as thickeners and preservatives) need to be solved. Summary of the Invention

[0007] The present invention provides an anti-aging, repair mask with stable high permeability and a preparation method thereof.

[0008] The present invention provides a mask with anti-aging, high-efficiency repair, anti-inflammatory and moisturizing functions, which uses mucopolysaccharide polysulfate as the main active ingredient and is supplemented with other natural ingredients. Through scientific proportioning and liposome encapsulation technology, the problems of poor permeability of active ingredients and single efficacy are solved.

[0009] The mask with anti-aging, high-efficiency repair, anti-inflammatory and moisturizing functions provided by the present invention is characterized in that it contains the following components by mass percentage:

[0010] Ingredient Mass percentage Mucoitin Polysulfate Liposome Suspension 10％-80％ Hyaluronic acid 1％-2％ Ceramide 0.3％-1％ Glycerol 5％-8％ Butanediol 3％-8％ Deionized water Up to 100%

[0011] Preferably, the above-mentioned mask contains the following components by mass percentage:

[0012] Ingredient Mass percentage Mucoitin Polysulfate Liposome Suspension 30％-70％ Hyaluronic acid 1％-2％ Ceramide 0.3％-1％ Glycerol 5％-8％ Butanediol 3％-8％ Deionized water Up to 100%

[0013] The above-mentioned mask may also contain pharmaceutically acceptable preservatives for the human body and its skin. Optional preservatives include phenoxyethanol, p-hydroxyacetophenone, potassium sorbate, sodium benzoate, pentylene glycol, octyldecanol, methylparaben, nipagin ester, etc. The content of preservatives in the mask is generally 0.1-1%.

[0014] The formula of the mask generally contains moisture and nutrients, which are ideal media for microorganisms such as bacteria and fungi. If the mask is contaminated by microorganisms, the microorganisms will multiply rapidly, resulting in product deterioration, and skin infections, allergies and other problems may occur when users use it. When the mask is in large packaging, that is, a single package contains multiple single-use doses, an appropriate amount of preservative can be selected to prevent the mask from being contaminated by microorganisms and deteriorating after the package is opened; when the mask is in single-dose packaging, preservatives can be selected not to be added, and aseptic production processes (sterilization + aseptic packaging) and / or inert gases (such as nitrogen) can be filled into individual packages before packaging to inhibit the production of microorganisms.

[0015] Masks can be classified into patch masks, smear masks, peel-off masks, and mask powders according to their forms. The mask provided by the present invention can be a smear mask, that is, the mask is directly and evenly coated on the skin surface and left standing for a period of time (such as 10 - 15 minutes) before use. The mask of the present invention can also be used as the matrix of a patch mask (the mask is used together with a mask cloth), that is, the mask of the present invention is coated on the mask cloth as the matrix, packaged, and then sold or directly used. The mask cloth can be made of materials with liquid absorption and skin-friendly functions such as non-woven fabric, tencel, biofiber, and silk. When the mask of the present invention is used together with the mask cloth, the mask can be pre-coated on the mask cloth or the two can be pre-mixed and then packaged together, or a separate compartment design can be adopted, that is, the mask and the mask cloth are separately and independently packaged, and the user mixes them by himself before use.

[0016] When choosing to use the mucopolysaccharide polysulfate mask of the present invention on the face by coating: After cleansing the face, take an appropriate amount of the mask and evenly apply it on the face, avoiding the eye area and lips. After standing for 15 - 20 minutes, wash it off with clean water. It is recommended to use it 2 - 3 times a week.

[0017] The above-mentioned mask is characterized in that the mucopolysaccharide polysulfate liposome suspension is prepared from the following prescription by mass percentage:

[0018] Ingredient Mass percentage Function description Mucoitin Polysulfate (MPS) 2-10％ Core active ingredient Lecithin 2-5％ Liposome membrane material, forming a bilayer Cholesterol 0.1-1.5％ Stabilize the liposome structure and reduce leakage Tween 80 0.1-0.5％ Surfactant, regulating dispersibility Vitamin E 0.01-0.1％ Prevent lipid oxidation Deionized water Balance to 100% Solvent

[0019] Preferably, the above-mentioned mask is characterized in that the mucopolysaccharide polysulfate liposome suspension is prepared from the following prescription by mass percentage:

[0020]

[0021]

[0022] The above-mentioned mask is characterized in that the hyaluronic acid is selected from high-molecular-weight hyaluronic acid, low-molecular-weight hyaluronic acid, or any combination of the two in any proportion; preferably, the hyaluronic acid is selected from high-molecular-weight hyaluronic acid, low-molecular-weight hyaluronic acid, or a combination of the two in a mass ratio of (0.5 - 2):1. More preferably, the hyaluronic acid is a combination of high-molecular-weight hyaluronic acid and low-molecular-weight hyaluronic acid in a mass ratio of 1:1.

[0023] The above-mentioned hyaluronic acid does not include medium-molecular-weight hyaluronic acid. The molecular weight of the high-molecular-weight hyaluronic acid is higher than 2000KDa; the molecular weight of the low-molecular-weight hyaluronic acid is between 10KDa and 500KDa; the molecular weight of the medium-molecular-weight hyaluronic acid is between 500KDa and 2000KDa.

[0024] In the MPS test of facial masks containing hyaluronic acid with different molecular weights by the technical personnel of the present invention, it was found that under the same conditions, the moisturizing or deep repair effect of MPS facial masks using high molecular weight hyaluronic acid, low molecular weight hyaluronic acid or a mixture of both is better than that of MPS facial masks using medium molecular weight hyaluronic acid. In addition, the effect of using a mixture of high and low molecular weight hyaluronic acids is also better than that of using only one of the hyaluronic acids alone. There is a complementary mechanism of action between high and low molecular weight hyaluronic acids in MPS facial masks: when used in combination, high molecular weight hyaluronic acid forms a water-locking protective film on the skin surface, and low molecular weight hyaluronic acid penetrates into the deep layer of the skin to replenish water, which can act on both the skin surface and deep layer simultaneously, forming a complete moisturizing system, making the effect of the MPS facial mask more comprehensive and lasting.

[0025] For the above-mentioned facial mask, the content (mass percentage concentration) of polysulfated mucopolysaccharide in the polysulfated mucopolysaccharide liposome suspension is 2-10%; preferably, the content of polysulfated mucopolysaccharide in the polysulfated mucopolysaccharide liposome suspension is 2-8%; more preferably, the content of polysulfated mucopolysaccharide in the polysulfated mucopolysaccharide liposome suspension is 5-8%.

[0026] Ceramide is the main component of the intercellular lipid in the stratum corneum of the skin, which is composed of a long-chain amino alcohol (LCB) and a fatty acid chain (FA) connected by forming an amide bond. According to the number and position of hydroxyl groups and double bonds, LCB can be divided into five types: dihydrosphingosine (DS), sphingosine (S), phytosphingosine (P), 6-hydroxysphingosine (H) and 4,14-sphingosine (SD). The FA in ceramide can also be divided into four types in the human body: non-hydroxy (N), α-hydroxy (A), ω-hydroxy (O) and esterified ω-hydroxy fatty acid (EO). According to the combination of LCB and fatty acid, ceramide can be divided into 20 classes. In the skin, changes in ceramide content, subclass changes and chain length changes will all affect the skin barrier function.

[0027] The researchers of the present invention found that compared with choosing other types of ceramide, using ceramide EOP and / or the combination of ceramide EOP and ceramide NS in the facial mask of the present invention, especially the MPS facial mask using the combination of ceramide EOP and ceramide NS, can be suitable for a wider range of skin types, and can play a special protective and repair role for sensitive skin. Adding the combination of ceramide EOP and ceramide NS to the MPS facial mask can make full use of the respective advantages of the two ceramides, and can synergistically enhance multiple effects such as extensive moisturizing, repair and scar removal together with MPS.

[0028] The facial mask of the present invention has passed the test. Under the same conditions, the facial mask with the technical solution of adding ceramide EOP and / or the combination of ceramide EOP and ceramide NS has a certain shortening in the time required for skin repair or scar removal on different types of skin compared to the facial mask with the technical solution of selecting other ceramides; after the same frequency and duration of use (such as using it twice a day for 2 weeks), it is observed that the skin of the facial mask with the technical solution of ceramide EOP and / or the combination of ceramide EOP and ceramide NS has shown a better trend of repair and improvement or more obvious effects, and has received better evaluations / ratings.

[0029] The facial mask described in the above-mentioned present invention is characterized in that the ceramide is ceramide EOP and / or the combination of ceramide EOP and ceramide NS; preferably, it is a mixed combination of ceramide EOP and ceramide NS.

[0030] The facial mask described in the above-mentioned present invention is characterized in that the ceramide is the combination of ceramide EOP and ceramide NS, and the mass ratio of ceramide EOP to ceramide NS is any ratio; preferably, the mass ratio of ceramide EOP to ceramide NS is (1-4):(1-4); more preferably, the mass ratio of ceramide EOP to ceramide NS is 1:1.

[0031] The facial mask described above is characterized in that the polysulfonic acid mucopolysaccharide liposome suspension is prepared by the following preparation method:

[0032] (1) Lipid dissolution: Dissolve lecithin, cholesterol, and vitamin E in an organic solvent, and evaporate under reduced pressure in a rotary evaporator until dry to form a uniform lipid film;

[0033] (2) Hydration and encapsulation: Dissolve MPS in deionized water, add Tween 80 and mix evenly to obtain an aqueous solution; add the aqueous solution to the lipid film obtained in step (1), and stir and hydrate at 50-60 °C for 30-60 minutes to form a crude liposome suspension;

[0034] (3) Particle size homogenization: Homogenize the crude liposome suspension in step (2) by a high-pressure homogenizer or ultrasonic treatment to control the liposome particle size within 50-200 nm;

[0035] (4) Purification: Remove free unencapsulated MPS by dialysis or ultrafiltration to obtain a polysulfonic acid mucopolysaccharide liposome suspension.

[0036] In the preparation method of the above-mentioned mucopolysaccharide polysulfate lipidosome suspension, in step (1), the organic solvent is a mixed solvent composed of solvent 1 and solvent 2; the solvent 1 is selected from chloroform, dichloromethane, ethyl acetate or any mixture thereof, preferably chloroform; the solvent 2 is selected from methanol, ethanol or any mixture thereof, preferably methanol; the ratio of solvent 1 to solvent 2 (v / v, volume ratio) is (1-2):1; the temperature of the reduced-pressure evaporation is 40-50 °C, and the vacuum degree is -0.1 MPa.

[0037] In the preparation method of the above-mentioned mucopolysaccharide polysulfate lipidosome suspension, in step (2), when the MPS is dissolved in deionized water, the pH of the solution is 5.5-6.5, or optionally the pH of the solution is adjusted to 5.5-6.5 with a pH regulator.

[0038] In the preparation method of the above-mentioned mucopolysaccharide polysulfate lipidosome suspension, in step (3), the working pressure of the high-pressure homogenizer treatment is 800-1500 bar, and the number of cycles is 3-5 times; the ultrasonic treatment is carried out in an ice bath, the ultrasonic power is 150-200 W, and the working time is 5-10 minutes.

[0039] The researchers of the present invention found that different ultrasonic powers and ultrasonic working times have a great influence on the particle size and liposome structure of the mucopolysaccharide polysulfate lipidosome suspension. When the ultrasonic power is low, extending the ultrasonic time cannot control the particle size within the ideal range; when the ultrasonic power is relatively high, the liposome particle size can be reduced, but the liposome structure is also damaged to varying degrees, resulting in the leakage of active substances from the liposomes. Therefore, the process of controlling the particle size by ultrasound is particularly crucial in the selection of ultrasonic power and working time. Similar situations also exist when using a high-pressure homogenizer to control the particle size. The working pressure and the number of cycles also have different effects on the particle size and leakage of the liposomes of the present invention. When the ultrasonic power and / or the ultrasonic time are reduced, or the working pressure and / or the number of cycles of the high-pressure homogenizer are reduced, the particle size of the obtained MPS liposomes is larger.

[0040] The researchers of the present invention also found that in the present invention, the addition of vitamin E can reduce the drug leakage during the particle size homogenization of liposomes. After the particle size homogenization step is carried out in the liposome solution containing vitamin E, the drug leakage condition is significantly lower than that of the liposome solution without vitamin E (the leakage rate is lower than 8% vs 15-40%), especially when adopting the production process of obtaining liposomes with smaller particle sizes.

[0041] In the preparation method of the above-mentioned mucopolysaccharide polysulfate liposome suspension, in step (4), the membrane selected for the dialysis or ultrafiltration method is a suitable membrane that can filter MPS and retain MPS liposomes under the corresponding working conditions. The membrane materials that can be selected include polysulfone, polyethersulfone, regenerated cellulose, etc., and the specification can be 0.2 μm.

[0042] The content of MPS in the mucopolysaccharide polysulfate liposome suspension obtained in the above step (4) can be determined by known detection methods. According to the measured MPS content and the target content of MPS in the final facial mask, the feeding amount of the mucopolysaccharide polysulfate liposome suspension used in the formulated facial mask prescription can be calculated. In the present invention, the content (mass percentage concentration) of MPS in the mucopolysaccharide polysulfate liposome suspension for preparing the mucopolysaccharide polysulfate facial mask can be 2-10%; preferably, the content of mucopolysaccharide polysulfate in the mucopolysaccharide polysulfate liposome suspension can be 2-8%; more preferably, the content of mucopolysaccharide polysulfate in the mucopolysaccharide polysulfate liposome suspension can be 5-8%.

[0043] In the mucopolysaccharide polysulfate liposome suspension of the present invention, after testing, the amount of free or leaked mucopolysaccharide polysulfate is not more than 8%; further, the amount of free or leaked mucopolysaccharide polysulfate is not more than 5%; still further, the amount of free or leaked mucopolysaccharide polysulfate is not more than 3%; still further, the amount of free or leaked mucopolysaccharide polysulfate can be not more than 1%.

[0044] The above-mentioned facial mask is characterized in that the facial mask is prepared by the following method:

[0045] (1) Heat deionized water to 70-80 °C, add hyaluronic acid and stir until completely dissolved.

[0046] (2) Cool down to 40-50 °C, add glycerol, butanediol, ceramide in sequence, and optionally add a preservative and stir evenly.

[0047] (3) Add the mucopolysaccharide polysulfate liposome suspension and stir evenly, filter, and fill to obtain the finished product.

[0048] It can be understood that those skilled in the art can calculate the feeding amount of the mucopolysaccharide polysulfate liposome suspension according to the content of mucopolysaccharide polysulfate measured in the mucopolysaccharide polysulfate liposome suspension and the content of mucopolysaccharide polysulfate in the target facial mask. By adjusting the feeding amount of the mucopolysaccharide polysulfate liposome suspension, the mass concentration of mucopolysaccharide polysulfate in the final facial mask can be more accurately controlled.

[0049] The mucopolysaccharide polysulfate liposome facial mask of the present invention contains 1% to 7% of mucopolysaccharide polysulfate; preferably, the content is 1% to 5%; more preferably, the proportion is 1% to 2%.

[0050] The mucopolysaccharide polysulfate facial mask of the present invention has the effects of inhibiting inflammatory reactions, reducing the redness and swelling caused by sensitivity or acne, improving local blood circulation, repairing the skin barrier, enhancing the skin's defense against external stimuli, promoting tissue regeneration, inhibiting scar formation, and softening scars.

[0051] Experiments have shown that the facial mask containing MPS of the present invention can improve the skin barrier function (trans-epidermal water loss value TEWL) by 15% - 25% (compared with the control group), and reduce inflammatory factors (such as IL-6) by 20% - 40%.

[0052] In the present invention, the term "pharmaceutically acceptable" refers to those compounds, materials, compositions, and / or dosage forms that are within the scope of reliable medical judgment, suitable for contact with human and animal tissues, without excessive toxicity, irritation, allergic reactions, or other problems or complications, and are commensurate with a reasonable benefit / risk ratio.

[0053] In the present invention, the term "comprising" or "including" can be open-ended, semi-closed, and closed. In other words, the term also includes "consisting essentially of" or "consisting of".

[0054] In the present invention, the term "hydration" refers to the process in which a lipid film absorbs water and gradually swells, peels off, and finally forms liposomes after contacting with an aqueous phase. Specifically, it includes: (1) Lipid water absorption and swelling: After the dry lipid film contacts the aqueous phase, the hydrophilic heads of phospholipid molecules combine with water, and the hydrophobic tails arrange to form a bilayer membrane structure, and the film gradually expands. (2) Liposome formation: Under the action of stirring (shearing force) and heating (50 - 60 °C, close to the lipid phase transition temperature), the swollen lipid film is dispersed into single-layer or multi-layer vesicles (liposomes), encapsulating the drug (MPS) and surfactant (Tween 80, assisting in stabilizing liposomes or improving drug solubility) in the aqueous phase.

[0055] In the present invention, the term "optionally" means that it can be selected or not selected.

[0056] In the present invention, "mass percentage" or "% (w / w)" is a way of expressing mass concentration, indicating the number of grams of solute contained in every 100 g of solution. For example, 20% (w / w) means that every 100 g of solution contains 20 g of solute. When expressed in a prescription, it can be understood that the total mass of all raw and auxiliary materials is 100%, and the corresponding percentage mass of the raw and auxiliary materials is fed. Description of the Drawings

[0057] None. Detailed implementation manners

[0058] To make the objectives, technical solutions and advantages of the present invention clearer and more understandable, the following further details the present invention through specific embodiments. Obviously, the described embodiments are only some preferred embodiments of the present invention, rather than all embodiments.

[0059] Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative efforts fall within the scope of protection of the present invention. It should be understood that these embodiments are only used to illustrate the present invention and not to limit the scope of the present invention.

[0060] For the experimental methods without specific conditions noted in the following embodiments, they are generally carried out under conventional conditions or according to the conditions recommended by the manufacturer.

[0061] Embodiment 1:

[0062] Prescription composition

[0063]

[0064]

[0065] Preparation method:

[0066] a) Lipid dissolution: Dissolve lecithin, cholesterol, and vitamin E in chloroform-methanol (volume ratio 2:1), and evaporate under reduced pressure in a rotary evaporator (temperature 45°C, vacuum -0.1 MPa) to form a uniform lipid film.

[0067] b) Hydration and MPS encapsulation: Dissolve MPS in deionized water, adjust the pH to 5.5 - 6.5, add Tween 80, and mix evenly. Add the aqueous solution to the lipid film, keep the water bath temperature at 50 - 60°C, stir and hydrate for 30 - 60 minutes to form a crude lipidosome suspension. c) Particle size homogenization: Pass the crude suspension through a high-pressure homogenizer (pressure 1000 bar, cycle 3 times) or ultrasonic treatment (ice bath, power 200 W, 5 - 10 minutes) to control the lipidosome particle size within 50 - 200 nm.

[0068] d) Purification: Remove the unencapsulated MPS by dialysis or ultrafiltration to obtain a mucoitin polysulfate lipidosome suspension.

[0069] e) Heat deionized water to 75°C, add hyaluronic acid, and stir until completely dissolved.

[0070] f) Cool down to 45°C, and sequentially add glycerin, butanediol, and ceramide, and stir evenly.

[0071] g) Add the mucopolysaccharide polysulfate liposome suspension, stir evenly, filter, and fill to obtain the finished product.

[0072] Example 2:

[0073] Prescription composition

[0074]

[0075]

[0076] Preparation method:

[0077] a) Lipid dissolution: Dissolve lecithin, cholesterol, and vitamin E in chloroform-methanol (2:1, v / v). Evaporate under reduced pressure in a rotary evaporator (temperature 45°C, vacuum -0.1 MPa) to form a uniform lipid film.

[0078] b) Hydration and MPS encapsulation: Dissolve MPS in deionized water, adjust the pH to 5.5 - 6.5, add Tween 80, and mix evenly.

[0079] Add the aqueous solution to the lipid film, keep the water bath temperature at 50 - 60°C, stir and hydrate for 30 - 60 minutes to form a crude liposome suspension.

[0080] c) Particle size homogenization: Pass the crude suspension through a high-pressure homogenizer (pressure 1000 bar, circulate 3 times) or ultrasonic treatment (ice bath, power 200 W, 5 - 10 minutes) to control the liposome particle size within 50 - 200 nm.

[0081] d) Purification: Remove the unencapsulated MPS by dialysis or ultrafiltration to obtain the mucopolysaccharide polysulfate liposome suspension.

[0082] e) Heat the deionized water to 80°C, add hyaluronic acid, and stir until completely dissolved.

[0083] f) Cool down to 50°C, sequentially add glycerin, butanediol, and ceramide, and stir evenly.

[0084] Add the mucopolysaccharide polysulfate liposome suspension, stir evenly, filter, and fill to obtain the finished product.

[0085] Example 3:

[0086] Prescription composition

[0087]

[0088]

[0089] Preparation method:

[0090] a) Lipid dissolution: Dissolve lecithin, cholesterol, and vitamin E in an organic solvent (such as a chloroform-methanol mixture, ratio 2:1). Evaporate under reduced pressure in a rotary evaporator to form a uniform lipid film (temperature 45°C, vacuum <0.1 MPa).

[0091] b) Hydration and MPS encapsulation: Dissolve MPS in deionized water (or buffer solution, pH 5.5 - 6.5), add Tween 80, and mix evenly. Add the aqueous solution to the lipid film, with the water bath temperature at 50 - 60°C, stir and hydrate for 30 - 60 minutes to form a crude liposome suspension.

[0092] c) Particle size homogenization: Pass the crude suspension through a high-pressure homogenizer (pressure 1000 bar, circulate 3 times) or ultrasonic treatment (ice bath, power 200 W, 5 - 10 minutes) to control the liposome particle size within 50 - 200 nm.

[0093] d) Purification: Remove the unencapsulated MPS by dialysis or ultrafiltration to obtain a mups liposome suspension.

[0094] e) Heat deionized water to 70°C, add hyaluronic acid, and stir until completely dissolved.

[0095] f) Cool down to 40°C, add glycerol, butanediol, and ceramide in sequence, and stir evenly.

[0096] g) Add the mups liposome suspension, stir evenly, filter, and fill to obtain the finished product.

[0097] Test Example 1 Transdermal Absorption Rate Test

[0098] Preparation of mups ordinary mask: Dissolve MPS in deionized water (or buffer solution, pH 5.5 - 6.5), add Tween 80, and mix evenly; heat deionized water to 70°C, add hyaluronic acid, and stir until completely dissolved; cool down to 40°C, add glycerol, butanediol, and ceramide in sequence, and stir evenly. Filter and fill to obtain the finished product.

[0099] Test method: Using mouse skin as the carrier, fix it between the supply chamber and the receiving chamber of the Franz diffusion cell, fix the diffusion cell in the transdermal absorption diffusion instrument, and under the condition of turning on the magnetic stirrer and constant temperature water bath, add the samples of the mask of the present invention, large particle size liposome MPS mask, and ordinary MPS mask to the skin surface of the chamber for transdermal experiments.

[0100] Effect of mups liposome masks with different particle sizes and mups ordinary masks on transdermal absorption rate

[0101]

[0102] Test Example 2: Effect Verification

[0103] (1) Moisturizing effect verification of the facial mask

[0104] The skin moisture content before and after using the facial mask was measured with a skin moisture tester. The results showed that the skin moisture content increased significantly after using the facial mask, and the moisturizing effect could last for more than 24 hours.

[0105] (2) Anti-inflammatory and anti-aging effects:

[0106] Verify the inhibitory effect of the facial mask on inflammatory factors (such as TNF-α, IL-6, IL-1β) and clarify the anti-inflammatory mechanism.

[0107] Test method:

[0108] Cell model: The cell type was selected as mouse macrophages (RAW264.7). The UVB irradiation inflammation induction method was used, and UVB (20 - 50mJ / cm 2 ) induced oxidative stress and inflammation.

[0109] Experimental grouping:

[0110] Blank control group: Untreated cells.

[0111] Inflammatory model group: Cells were irradiated with UVB without adding samples.

[0112] Positive control group: Cells were irradiated with UVB + other anti-inflammatory facial masks.

[0113] Experimental group: Cells were irradiated with UVB + Examples 1 - 3.

[0114] Test method:

[0115] ① Sample preparation: Take an appropriate amount of cell culture supernatant samples.

[0116] ② Sample addition: Add the samples, standards, and controls to each well of the microplate and incubate for a period of time to allow IL-6 to bind to the capture antibody.

[0117] ③ Add detection antibody: Add the detection antibody labeled with an enzyme, incubate for the reaction, and ensure that the detection antibody binds to IL-6 in the sample.

[0118] ④ Washing: Wash the microplate with the washing solution to remove unbound components, ensuring that only the antibody and label bound to IL-6 remain in the wells.

[0119] ⑤ Color reaction: Add the substrate solution, and the substrate reacts with the enzyme to produce a measurable color change.

[0120] ⑥Measurement: Use an ELISA reader to measure the signal intensity of the color change and calculate the concentration of IL-6 in the sample based on the standard curve.

[0121] Test results: The concentration of IL-6 in the cell supernatant was detected by ELISA to evaluate the level of inflammatory factors. The IL-6 level in the experimental group was reduced by 20%-40% compared with the positive control group.

[0122] Experimental Example 3: Animal Model Test

[0123] To evaluate the efficacy of topical facial masks in alleviating skin inflammation (e.g., improvement in erythema, swelling, and tissue pathology) in animals.

[0124] (1) Animal model: SD rats were selected (6-8 rats per group). UVB irradiation (100-200 mJ / cm 2 ) induces phototoxic erythema.

[0125] (2) Experimental groups:

[0126] Blank control group: no treatment.

[0127] Model group: UVB irradiated cells + no treatment.

[0128] Positive control group: UVB irradiated cells + matrix mask without MPS (applied once a day for 3-7 consecutive days).

[0129] Experimental group: UVB irradiated cells + Example 1-3 (applied once a day for 3-7 consecutive days).

[0130] (3) Detection method:

[0131] Use a skin colorimeter The a* (erythema index) data of the blank group, model group, control group and experimental group at each observation time point were measured respectively.

[0132] (4) Test and results

[0133] The change of ear thickness was measured by vernier caliper: the ear thickness of the experimental group was reduced by 10%-15% compared with the positive control group.

[0134] The erythema index (a* value) was measured by skin colorimeter. The erythema area in the experimental group was reduced by 10%-17% compared with the positive control group.

[0135] Test Example 4: Skin repair effect test

[0136] People with sensitive skin were screened and divided into an experimental group and a control group. The experimental group used a facial mask three times a week for four consecutive weeks; the control group used a matrix mask without active ingredients (placebo) three times a week for four consecutive weeks.

[0137] Detection method:: Gently place the sensor head of the transepidermal water loss (TEWL value) measuring instrument close to the skin surface of the test site, and start the instrument for testing. During the test, maintain the adhesion of the instrument to the skin surface to avoid external interference. After the test is completed, the instrument will display the corresponding water loss rate data.

[0138] Test results: The skin barrier function (TEWL value of transepidermal water loss) of the experimental group was improved by 15%-25% compared with that of the control group.

[0139] It can be seen from the above test examples that: The anti-aging and repair mask provided by the present invention uses polysulfated glycosaminoglycan as the main active ingredient, supplemented by other natural ingredients, and through scientific ratio and liposome encapsulation technology, it has good permeability, has the effects of anti-aging, moisturizing and repair, and is safe and non-irritating, suitable for various skin types.

Claims

1. A facial mask, characterized in that, It contains the following components by mass percentage: Preferably, the facial mask contains the following components by mass percentage: 。 2. The facial mask according to claim 1, characterized in that, The mucopolysaccharide polysulfate liposome suspension is prepared from the following prescription by mass percentage: ； Preferably, the mucopolysaccharide polysulfate liposome suspension is prepared from the following prescription by mass percentage: 。 3. The facial mask according to claim 1, characterized in that The hyaluronic acid is selected from high molecular weight hyaluronic acid, low molecular weight hyaluronic acid or any combination of the two in any proportion; preferably, the hyaluronic acid is selected from high molecular weight hyaluronic acid, low molecular weight hyaluronic acid or a combination of the two with a mass ratio of (0.5 - 2):1; more preferably, the hyaluronic acid is a combination of high molecular weight hyaluronic acid and low molecular weight hyaluronic acid with a mass ratio of 1:

1.

4. The facial mask according to claim 1, wherein The mass percentage concentration of mucopolysaccharide polysulfate in the mucopolysaccharide polysulfate liposome suspension is 2 - 10%; preferably, the content of mucopolysaccharide polysulfate in the mucopolysaccharide polysulfate liposome suspension is 2 - 8%; more preferably, the content of mucopolysaccharide polysulfate in the mucopolysaccharide polysulfate liposome suspension is 5 - 8%.

5. The facial mask according to claim 1, characterized in that, The ceramide is ceramide EOP and / or a combination of ceramide EOP and ceramide NS; preferably a mixture of ceramide EOP and ceramide NS.

6. The facial mask according to claim 5, wherein The ceramide is a combination of ceramide EOP and ceramide NS, and the mass ratio of ceramide EOP to ceramide NS is in any proportion; preferably, the mass ratio of ceramide EOP to ceramide NS is (1 - 4):(1 - 4); more preferably, the mass ratio of ceramide EOP to ceramide NS is 1:

1.

7. The facial mask according to claim 1 or 2, characterized in that, The mucopolysaccharide polysulfate liposome suspension is prepared by the following preparation method: (1) Lipid dissolution: Dissolve lecithin, cholesterol, and vitamin E in an organic solvent, and evaporate under reduced pressure in a rotary evaporator until dry to form a uniform lipid film; (2) Hydration and encapsulation: Dissolve mucopolysaccharide polysulfate in deionized water, add Tween 80 and mix evenly to obtain an aqueous solution; add the aqueous solution to the lipid film obtained in step (1), and stir and hydrate at 50 - 60 °C for 30 - 60 minutes to form a crude liposome suspension; (3) Particle size homogenization: Homogenize the crude liposome suspension in step (2) by a high-pressure homogenizer or ultrasonic treatment to control the liposome particle size within 50 - 200 nm; (4) Purification: Remove free and unencapsulated mucopolysaccharide polysulfate by dialysis or ultrafiltration to obtain the mucopolysaccharide polysulfate liposome suspension.

8. The facial mask according to claim 7, characterized in that, In step (1) of the preparation method of the mucopolysaccharide polysulfate liposome suspension, the organic solvent is a mixed solvent composed of solvent 1 and solvent 2; wherein, solvent 1 is selected from chloroform, dichloromethane, ethyl acetate or any mixture thereof, preferably chloroform; solvent 2 is selected from methanol, ethanol or any mixture thereof, preferably methanol; the volume ratio of solvent 1 to solvent 2 is (1 - 2):

1.

9. The facial mask according to any one of claims 1, 2 or 7, characterized in that, The amount of free mucopolysaccharide polysulfate contained in the mucopolysaccharide polysulfate liposome suspension is not more than 8%; preferably, the amount of free mucopolysaccharide polysulfate is not more than 5%; more preferably, the amount of free mucopolysaccharide polysulfate is not more than 3%; further preferably, the amount of free mucopolysaccharide polysulfate is not more than 1%.

10. The facial mask according to claim 1 or 2, characterized in that The mask is prepared by the following method: (1) Heat deionized water to 70 - 80 °C, add hyaluronic acid and stir until completely dissolved. (2) Cool down to 40 - 50 °C, add glycerol, butanediol, ceramide in sequence, and stir evenly after optionally adding preservatives. (3) Add the mucopolysaccharide polysulfate liposome suspension and stir evenly, filter, and fill to obtain the product.

Images